Allosteric modulation of monoamine transporters - new drug targets in depression

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 4, 2006, Pages 483-488

  Sanchez, Connie ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE; AA 21004; AA 21104; AGOMELATINE; AMIBEGRON; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESVENLAFAXINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; DOV 216303; ESCITALOPRAM; MIFEPRISTONE; N [3 [4 [4 (CYCLOHEXYLMETHYLSULFONAMIDO)BUTYL] 1 PIPERAZINYL]PHENYL]ACETAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; NS 2359; OSEMOZOTAN; PAROXETINE; R 673; SAREDUTANT; SEP 225289; SEROTONIN AGONIST; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VILAZODONE;

ALLOSTERISM; BINDING COMPETITION; BINDING SITE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; NONHUMAN; PROTEIN INTERACTION; REVIEW;

EID: 33846143846     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.019     Document Type: Review

References (25)

1. Bosker F.J., et al. Future antidepressants: what is in the pipeline and what is missing?. CNS Drugs 18 (2004) 705-732
2. Soudijn W., et al. Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. Drug Discov. Today 9 (2004) 728-752
3. Sánchez C., et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174 (2004) 163-176
4. Mathews C.K., et al. Biochemistry. 3rd edn (2000), Addison Wesley Longman
5. Hirschfeld R.M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61 Suppl. 6 (2000) 4-6
6. --dependent neurotransmitter transporters. Nature 437 (2005) 215-223
7. Hastrup H., et al. Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys 306 at the extracellular end of the sixth transmembrane segment. Proc. Natl. Acad. Sci. U S A 98 (2001) 10055-10060
8. Schmid J.A., et al. Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J. Biol. Chem. 276 (2001) 3805-3810
9. Larsen M.B., et al. The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors: a species-scanning mutagenesis study. J. Biol. Chem. 279 (2004) 42147-42156
10. Henry L.K., et al. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281 (2006) 2012-2023
11. Mørk A., et al. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45 (2003) 167-173
12. Altamirano A.V., and Frazer A. Comparison of the effects of the enantiomers of citalopram on the clearance of exogenous serotonin. Biol. Psychiatry 57 (2005) 178S-179S
13. Sánchez C., et al. Escitalopram, the S-(π)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167 (2003) 353-362
14. Storustovu S., et al. R-citalopram functionally antagonizes escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br. J. Pharmacol. 142 (2003) 172-180
15. El Mansari, M. et al. (2006) Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int. J. Neuropsychopharmacol. (in press)
16. 3H]paroxetine binding to platelet and neuronal membranes. Eur. J. Pharmacol. 119 (1985) 1-8
17. 3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur. J. Pharmacol. 206 (1991) 243-250
18. Chen F., et al. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J. Neurochem. 92 (2005) 21-28
19. Chen F., et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. 15 (2005) 193-198
20. Neubauer H.A., et al. Dissection of an allosteric mechanism on the serotonin transporter: A cross-species study. Mol. Pharmacol. 69 (2006) 1242-1250
21. Nandi A., et al. Identification and characterization of a novel allosteric modulator (SoRI-6238) of the serotonin transporter. Synapse 53 (2004) 176-183
22. Boos T.L., et al. Structure-activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl) methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piper idine, an allosteric modulator of the serotonin transporter. Bioorg. Med. Chem. 14 (2006) 3967-3973
23. Plenge P., and Mellerup E.T. An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol. Toxicol. 80 (1997) 197-201
24. Kasper S., et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int. Clin. Psychopharmacol. 21 (2006) 105-110
25. Sánchez C., et al. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin. Pharmacol. Toxicol. 99 (2006) 91-95